At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MDGL Madrigal Pharmaceuticals
Trading 10-29 11:46:08 EDT
440.66
+9.66
+2.24%
High445.63Low434.45Vol67.37K
Open434.45D1 Closing431.00Amplitude2.59%
Mkt Cap10.16BTradable Cap6.05BTotal Shares23.06M
T/O29.73MT/O Rate0.49%Tradable Shares13.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Earning Preview: Madrigal Pharmaceuticals this quarter’s revenue is expected to increase by 63.47%, and institutions are predominantly bullish
Earnings Agent  ·  10-27 14:43
Earning Preview: Madrigal Pharmaceuticals this quarter’s revenue is expected to increase by 63.47%, and institutions are predominantly bullish
Madrigal Reports Real-World Data Showing Rezdiffra Improves Liver Health Measures Through 12 Months
Reuters  ·  10-27 20:09
Madrigal Reports Real-World Data Showing Rezdiffra Improves Liver Health Measures Through 12 Months
Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH
GlobeNewswire  ·  10-27 20:00
Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH
Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026
GlobeNewswire  ·  10-20
Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026
BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says
MT Newswires Live  ·  10-19
BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says
Madrigal Pharmaceuticals price target lowered to $533 from $543 at BofA
TIPRANKS  ·  10-19
Madrigal Pharmaceuticals price target lowered to $533 from $543 at BofA
BofA Securities Adjusts Price Target on Madrigal Pharmaceuticals to $533 From $543, Maintains Neutral Rating
MT Newswires Live  ·  10-19
BofA Securities Adjusts Price Target on Madrigal Pharmaceuticals to $533 From $543, Maintains Neutral Rating
Bank of America Securities Reaffirms Their Hold Rating on Madrigal Pharmaceuticals (MDGL)
TIPRANKS  ·  10-19
Bank of America Securities Reaffirms Their Hold Rating on Madrigal Pharmaceuticals (MDGL)
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Madrigal Pharmaceuticals (MDGL)
TIPRANKS  ·  10-18
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Madrigal Pharmaceuticals (MDGL)
Madrigal Pharmaceuticals Grants 9,642 Restricted Stock Units to 26 New Employees
Reuters  ·  10-16
Madrigal Pharmaceuticals Grants 9,642 Restricted Stock Units to 26 New Employees
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  10-16
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  10-16
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
US High Growth Tech Stocks to Watch for Potential Portfolio Boost
Simply Wall St.  ·  10-15
US High Growth Tech Stocks to Watch for Potential Portfolio Boost
Madrigal Pharmaceuticals (MDGL) Publishes Rezdiffra Genetic Analysis, Is The Stock Cheap?
Simply Wall St.  ·  10-15
Madrigal Pharmaceuticals (MDGL) Publishes Rezdiffra Genetic Analysis, Is The Stock Cheap?
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX), Beam Therapeutics (BEAM) and Madrigal Pharmaceuticals (MDGL)
TIPRANKS  ·  10-14
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX), Beam Therapeutics (BEAM) and Madrigal Pharmaceuticals (MDGL)
Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
GlobeNewswire  ·  10-06
Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
Barclays Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
TIPRANKS  ·  09-30
Barclays Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
HCA, Tenet, CoreWeave, Microsoft, Madrigal Trending With Analysts
TIPRANKS  ·  09-26
HCA, Tenet, CoreWeave, Microsoft, Madrigal Trending With Analysts
Madrigal Pharmaceuticals Price Target Announced at $704.00/Share by Goldman Sachs
Dow Jones  ·  09-24
Madrigal Pharmaceuticals Price Target Announced at $704.00/Share by Goldman Sachs
Madrigal Pharmaceuticals resumed with a Buy at Goldman Sachs
TIPRANKS  ·  09-24
Madrigal Pharmaceuticals resumed with a Buy at Goldman Sachs

Introduction

Company Name.
Madrigal Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.
Issue price:
--